Craig R Lee1, Vindhya B Sriramoju2, Alexandra Cervantes2, Lucius A Howell2, Nicholas Varunok2, Shivanshu Madan2, Kasey Hamrick2, Melissa J Polasek2, John Andrew Lee2, Megan Clarke2, Jonathan D Cicci2, Karen E Weck2, George A Stouffer2. 1. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy (C.R.L., A.C., K.H., M.J.P., J.A.L.), UNC Center for Pharmacogenomics and Individualized Therapy (C.R.L., K.E.W.), UNC McAllister Heart Institute (C.R.L., G.A.S.), Division of Cardiology, UNC School of Medicine (V.B.S., L.A.H., N.V., S.M., G.A.S.), Department of Pharmacy, UNC HealthCare Medical Center (M.C., J.D.C.), and Department of Pathology and Laboratory Medicine, UNC School of Medicine (K.E.W.), University of North Carolina at Chapel Hill. craig_lee@unc.edu. 2. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy (C.R.L., A.C., K.H., M.J.P., J.A.L.), UNC Center for Pharmacogenomics and Individualized Therapy (C.R.L., K.E.W.), UNC McAllister Heart Institute (C.R.L., G.A.S.), Division of Cardiology, UNC School of Medicine (V.B.S., L.A.H., N.V., S.M., G.A.S.), Department of Pharmacy, UNC HealthCare Medical Center (M.C., J.D.C.), and Department of Pathology and Laboratory Medicine, UNC School of Medicine (K.E.W.), University of North Carolina at Chapel Hill.
Abstract
BACKGROUND: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of using CYP2C19 genotype-guided dual antiplatelet therapy (DAPT) selection in practice remains unclear. METHODS: A single-center observational study was conducted in 1193 patients who underwent percutaneous coronary intervention and received DAPT after implementation of an algorithm that recommends CYP2C19 testing in high-risk patients and alternative DAPT (prasugrel or ticagrelor) in LOF allele carriers. The frequency of genotype testing and alternative DAPT selection were the primary implementation end points. Risk of major adverse cardiovascular or cerebrovascular and clinically significant bleeding events over 12 months were compared across genotype and DAPT groups by proportional hazards regression. RESULTS: CYP2C19 genotype was obtained in 868 (72.8%) patients. Alternative DAPT was prescribed in 186 (70.7%) LOF allele carriers. CYP2C19 testing (P<0.001) and alternative DAPT use in LOF allele carriers (P=0.001) varied over time. Risk for major adverse cardiovascular or cerebrovascular was significantly higher in LOF carriers prescribed clopidogrel versus alternative DAPT (adjusted hazard ratio, 4.65; 95% confidence interval, 2.22-10.0; P<0.001), whereas no significant difference was observed in those without a LOF allele (adjusted hazard ratio, 1.37; 95% confidence interval, 0.72-2.85; P=0.347). Bleeding event rates were similar across groups (log-rank P=0.816). CONCLUSIONS: Implementing CYP2C19 genotype-guided DAPT is feasible and sustainable in a real-world setting but challenging to maintain at a consistently high level of fidelity. The higher risk of major adverse cardiovascular or cerebrovascular associated with clopidogrel use in CYP2C19 LOF allele carriers suggests that use of genotype-guided DAPT in practice may improve clinical outcomes.
BACKGROUND:CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of using CYP2C19 genotype-guided dual antiplatelet therapy (DAPT) selection in practice remains unclear. METHODS: A single-center observational study was conducted in 1193 patients who underwent percutaneous coronary intervention and received DAPT after implementation of an algorithm that recommends CYP2C19 testing in high-risk patients and alternative DAPT (prasugrel or ticagrelor) in LOF allele carriers. The frequency of genotype testing and alternative DAPT selection were the primary implementation end points. Risk of major adverse cardiovascular or cerebrovascular and clinically significant bleeding events over 12 months were compared across genotype and DAPT groups by proportional hazards regression. RESULTS:CYP2C19 genotype was obtained in 868 (72.8%) patients. Alternative DAPT was prescribed in 186 (70.7%) LOF allele carriers. CYP2C19 testing (P<0.001) and alternative DAPT use in LOF allele carriers (P=0.001) varied over time. Risk for major adverse cardiovascular or cerebrovascular was significantly higher in LOF carriers prescribed clopidogrel versus alternative DAPT (adjusted hazard ratio, 4.65; 95% confidence interval, 2.22-10.0; P<0.001), whereas no significant difference was observed in those without a LOF allele (adjusted hazard ratio, 1.37; 95% confidence interval, 0.72-2.85; P=0.347). Bleeding event rates were similar across groups (log-rank P=0.816). CONCLUSIONS: Implementing CYP2C19 genotype-guided DAPT is feasible and sustainable in a real-world setting but challenging to maintain at a consistently high level of fidelity. The higher risk of major adverse cardiovascular or cerebrovascular associated with clopidogrel use in CYP2C19 LOF allele carriers suggests that use of genotype-guided DAPT in practice may improve clinical outcomes.
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Kristin W Weitzel; Amanda R Elsey; Taimour Y Langaee; Benjamin Burkley; David R Nessl; Aniwaa Owusu Obeng; Benjamin J Staley; Hui-Jia Dong; Robert W Allan; J Felix Liu; Rhonda M Cooper-Dehoff; R David Anderson; Michael Conlon; Michael J Clare-Salzler; David R Nelson; Julie A Johnson Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-10 Impact factor: 3.908
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875
Authors: Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson Journal: JACC Cardiovasc Interv Date: 2017-11-01 Impact factor: 11.195
Authors: J A Luzum; R E Pakyz; A R Elsey; C E Haidar; J F Peterson; M Whirl-Carrillo; S K Handelman; K Palmer; J M Pulley; M Beller; J S Schildcrout; J R Field; K W Weitzel; R M Cooper-DeHoff; L H Cavallari; P H O'Donnell; R B Altman; N Pereira; M J Ratain; D M Roden; P J Embi; W Sadee; T E Klein; J A Johnson; M V Relling; L Wang; R M Weinshilboum; A R Shuldiner; R R Freimuth Journal: Clin Pharmacol Ther Date: 2017-06-09 Impact factor: 6.875
Authors: L H Cavallari; A L Beitelshees; K V Blake; L G Dressler; J D Duarte; A Elsey; J N Eichmeyer; P E Empey; J P Franciosi; J K Hicks; A M Holmes; Ljb Jeng; C R Lee; J J Lima; N A Limdi; J Modlin; A O Obeng; N Petry; V M Pratt; T C Skaar; S Tuteja; D Voora; M Wagner; K W Weitzel; R A Wilke; J F Peterson; J A Johnson Journal: Clin Transl Sci Date: 2017-03-14 Impact factor: 4.689
Authors: Janice B Schwartz; Kenneth E Schmader; Joseph T Hanlon; Darrell R Abernethy; Shelly Gray; Jacqueline Dunbar-Jacob; Holly M Holmes; Michael D Murray; Robert Roberts; Michael Joyner; Josh Peterson; David Lindeman; Ming Tai-Seale; Laura Downey; Michael W Rich Journal: J Am Geriatr Soc Date: 2018-12-07 Impact factor: 5.562
Authors: Rachel M Black; Alexis K Williams; Lindsay Ratner; Daniel J Crona; Tim Wiltshire; Karen E Weck; George A Stouffer; Craig R Lee Journal: Pharmacogenomics Date: 2020-04-28 Impact factor: 2.533
Authors: Alexis K Williams; Melissa D Klein; Jesse Martin; Karen E Weck; Joseph S Rossi; George A Stouffer; Craig R Lee Journal: Circ Genom Precis Med Date: 2019-02
Authors: Chelsea Gustafson; Megan N Gower; Alexis K Williams; Eric Pauley; Karen E Weck; Craig R Lee; George A Stouffer Journal: Circ Genom Precis Med Date: 2020-09-16
Authors: Nita A Limdi; Larisa H Cavallari; Craig R Lee; William B Hillegass; Ann M Holmes; Todd C Skaar; Maria Pisu; Chrisly Dillon; Amber L Beitelshees; Philip E Empey; Julio D Duarte; Vakaramoko Diaby; Yan Gong; Julie A Johnson; John Graves; Shawn Garbett; Zilu Zhou; Josh F Peterson Journal: Pharmacogenomics J Date: 2020-02-11 Impact factor: 3.550
Authors: Craig R Lee; Cameron D Thomas; Amber L Beitelshees; Sony Tuteja; Philip E Empey; James C Lee; Nita A Limdi; Julio D Duarte; Todd C Skaar; Yiqing Chen; Kelsey J Cook; James C Coons; Chrisly Dillon; Francesco Franchi; Jay Giri; Yan Gong; Rolf P Kreutz; Caitrin W McDonough; James M Stevenson; Karen E Weck; Dominick J Angiolillo; Julie A Johnson; George A Stouffer; Larisa H Cavallari Journal: Clin Pharmacol Ther Date: 2020-10-02 Impact factor: 6.875